Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer's disease

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

Donanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease.

This is because the current available evidence shows that the treatment effects for donanemab and for lecanemab were small with uncertain clinical meaningfulness, and the short trial durations limited the understanding of the treatments’ impact over the full course of the disease.

Given the uncertainty in clinical benefit and significant additional healthcare resources required to assess treatment eligibility and risks, as well as for regular magnetic resonance imaging (MRI) monitoring, funding these drugs would not represent a cost-effective use of healthcare resources and could place undue strain on the healthcare system.

Guidance_Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease (6 Feb 2026)

PES_Donanemab and lecanemab for treating early Alzheimer’s disease (6 Feb 2026)